HomeArticles2022 No.2Details

Clinical applications of basophil activation test: a review

Update:Apr. 25, 2022Total Views:1217Total Downloads:1162 DownloadMobile

Author: Ya-Dong GAO Jin-Jin ZHANG Guang-Hui LIU

Affiliation: Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Keywords: Basophils Basophil activation test Flow cytometry Allergen Allergic disease


Reference:Gao YD, Zhang JJ, Liu GH. Clinical applications of basophil activation test: a review[J]. Yixue Xinzhi Zazhi, 2022, 32(2): 148-155. DOI: 10.12173/j.issn.1004-5511.20211211476.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References

Basophils are one of the most important effector cells involved in IgE-mediated type I hypersensitivity and type 2 inflammation. Basophil activation test (BAT) simulates in vivo type I hyper-sensitivity. Flow cytometry is used in BAT to detect the expression level of specific surface markers on basophils after allergen stimulation, hence reflecting the degree of activation and status of basophils. As an allergen test in vitro, BAT shows good safety and high specificity. In clinical practice, it can be used for the auxiliary diagnosis of diseases such as food or drug allergy, airway allergic diseases, hymenoptera venom allergy and anaphylaxis. In addition, it can help to predict and monitor the efficacy of specific immunotherapy for different allergens. Allergen reagents, operational procedures and interpretation methods need to be further standardized to facilitate the popularization and application of BAT. 

Please download the PDF version to read the full text: download

1.Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmun-ity and other chronic conditions?[J]. Nat Rev Immunol, 2021, 21(11): 739-751. DOI: 10.1038/s41577-021-00538-7.

2.Tourlas K, Burman D. Allergy Testing[J]. Prim Care, 2016, 43(3): 363-374. DOI: 10.1016/j.pop.2016.04.001.

3.Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice[J]. Allergy, 2021, 76(8): 2420-2432. DOI: 10.1111/all.14747.

4.Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease[J]. Allergy, 2015, 70(11): 1393-1405. DOI: 10.1111/all.12698.

5.Kabashima K, Nakashima C, Nonomura Y, et al. Biomarkers for evaluation of mast cell and basophil activation[J]. Immunol Rev, 2018, 282(1): 114-120. DOI: 10.1111/imr.12639.

6.李璐, 潘庆军, 刘华锋. 嗜碱性粒细胞在Th2型免疫应答中的作用[J]. 免疫学杂志, 2015, 31(2): 176-180. [Li L, Pan QJ, Liu HF. The role of basophils in Th2-type immune response[J]. Im-munological Journal, 2015, 31(2): 176-180.] DOI: 10.13431/j.cnki.immunol.j.20150037.

7.Yamanishi Y, Miyake K, Iki M, et al. Recent advances in understanding basophil-mediated Th2 immune responses[J]. Immunol Rev, 2017, 278(1): 237-245. DOI: 10.1111/imr.12548.

8.Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediat-ed allergic inflammation by producing TSLP[J]. Nat Immunol, 2002, 3(7): 673-680. DOI: 10.1038/ni805.

9.Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation[J]. Nature, 2011, 477(7363): 229-233. DOI: 10.1038/nature10329.

10.Motomura Y, Morita H, Moro K, et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation[J]. Immunity, 2014, 40(5): 758-771. DOI: 10.1016/j.immuni.2014.04.013.

11.Imai Y, Yasuda K, Nagai M, et al. IL-33-induced atopic dermatitis-like inflammation in mice is mediated by group 2 innate lymphoid cells in concert with Basophils[J]. J Invest Der-matol, 2019, 139(10): 2185-2194.e3. DOI: 10.1016/j.jid.2019.04.016.

12.Hussain M, Borcard L, Walsh KP, et al. Basophil-derived IL-4 promotes epicutaneous anti-gen sensitization concomitant with the development of food allergy[J]. J Allergy Clin Im-munol, 2018, 141(1): 223-234.e5. DOI: 10.1016/j.jaci.2017.02.035.

13.高翠娥, 宋志强. 嗜碱性粒细胞活化试验在变态反应性疾病诊断中的应用[J]. 免疫学杂志, 2017, 33(4): 360-363. [Gao CE, Song ZQ. The application of basophil activation test in diagnosis of allergic diseases[J]. Immunological Journal, 2017, 33(4): 360-363.] DOI: 10.13431/j.cnki.immunol.j.20170064.

14.Sturm EM, Kranzelbinder B, Heinemann A, et al. CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation[J]. Cytometry B Clin Cytom, 2010, 78(5): 308-318. DOI: 10.1002/cyto.b.20526.

15.Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: in vitro testing[J]. J Al-lergy Clin Immunol, 2019, 143(1): 56-65. DOI: 10.1016/j.jaci.2018.09.022.

16.Nguyen KL, Gillis S, MacGlashan DW Jr. A comparative study of releasing and nonreleasing human basophils: nonreleasing basophils lack an early component of the signal trans-duction pathway that follows IgE cross-linking[J]. J Allergy Clin Immunol, 1990, 85(6): 1020-1029. DOI: 10.1016/0091-6749(90)90046-7.

17.Hemmings O, Kwok M, McKendry R, et al. Basophil activation test: old and new applica-tions in allergy[J]. Curr Allergy Asthma Rep, 2018, 18(12): 77. DOI: 10.1007/s118 82-018-0831-5.

18.Monneret G, Boumiza R, Gravel S. Effects of prostaglandin D(2) and 5-lipoxygenase prod-ucts on the expression of CD203c and CD11b by basophils[J]. J Pharmacol Exp Ther, 2005, 312(2): 627-634. DOI: 10.1124/jpet.104.074823.

19.Hennersdorf F, Florian S, Jakob A, et al. Identification of CD13, CD107a, and CD164 as nov-el basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation[J]. Cell Res, 2005, 15(5): 325-335. DOI: 10.1038/sj.cr.7290301.

20.Yoshimura C, Yamaguchi M, Iikura M, et al. Activation markers of human basophils: CD69 expression is strongly and preferentially induced by IL-3[J]. J Allergy Clin Immunol, 2002, 109(5): 817-823. DOI: 10.1067/mai.2002. 123532.

21.Zenarruzabeitia O, Vitallé J, Terrén I, et al. CD300c costimulates IgE-mediated basophil ac-tivation, and its expression is increased in patients with cow's milk allergy[J]. J Allergy Clin Immunol, 2019, 143(2): 700-711.e5. DOI: 10.1016/j.jaci.2018.05.022.

22.MacGlashan DW Jr. Basophil activation testing[J]. J Allergy Clin Immunol, 2013, 132(4): 777-787. DOI: 10.1016/j.jaci.2013.06.038.

23.Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and im-munotherapy[J]. Nat Rev Immunol, 2016, 16(12): 751-765. DOI: 10.1038/nri.2016.111.

24.Sampson HA, O'Mahony L, Burks AW, et al. Mechanisms of food allergy[J]. J Allergy Clin Immunol, 2018, 141(1): 11-19. DOI: 10.1016/j.jaci.2017.11.005.

25.范久亿, 邢燕, 周薇. 嗜碱性粒细胞活化试验在儿童食物过敏中的诊断价值[J]. 中华实用儿科临床杂志, 2017, 32(9): 714-717. [Fan JY, Xing Y, Zhou W. Diagnostic value of basophil activation test in food allergy in children[J]. Chinese Journal of Applied Clinical Pediatrics, 2017, 32(9): 714-717.] DOI: 10.3760/cma.j.issn.2095-428X.2017.09.020.

26.Santos AF, Douiri A, Bécares N, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children[J]. J Allergy Clin Immunol, 2014, 134(3): 645-652. DOI: 10.1016/j.jaci.2014.04.039.

27.van Erp FC, Knol EF, Pontoppidan B, et al. The IgE and basophil responses to Ara h 2 and Ara h 6 are good predictors of peanut allergy in children[J]. J Allergy Clin Immunol, 2017, 139(1): 358-360.e8. DOI: 10.1016/j.jaci. 2016.06.041.

28.Santos AF, Du Toit G, Douiri A, et al. Distinct parameters of the basophil activation test re-flect the severity and threshold of allergic reactions to peanut[J]. J Allergy Clin Immunol, 2015, 135(1): 179-186. DOI: 10.1016/j.jaci. 2014.09.001.

29.Patil SU, Steinbrecher J, Calatroni A, et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy[J]. J Allergy Clin Immunol, 2019, 144(5): 1310-1319.e4. DOI: 10.1016/j.jaci.2019.07.028.

30.Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper[J]. Allergy, 2016, 71(8): 1103-1134. DOI: 10.1111/all.12886.

31.Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity[J]. Allergy, 2019, 74(8): 1457-1471. DOI: 10.1111/all.13765.

32.Soyer O, Sahiner UM, Sekerel BE. Pro and contra: provocation tests in drug hypersensitivi-ty[J]. Int J Mol Sci, 2017, 18(7): 1437. DOI: 10.3390/ijms18071437.

33.Hausmann OV, Gentinetta T, Bridts CH, et al. The basophil activation test in immedi-ate-type drug allergy[J]. Immunol Allergy Clin North Am, 2009, 29(3): 555-566. DOI: 10.1016/j.iac.2009.04.011.

34.Marraccini P, Pignatti P, D Apos Alcamo A, et al. Basophil activation test application in drug hypersensitivity diagnosis: an empirical approach[J]. Int Arch Allergy Immunol, 2018, 177(2): 160-166. DOI: 10.1159/000490 116.

35.Salas M, Fernández-Santamaría R, Mayorga C, et al. Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy[J]. J Allergy Clin Immunol Pract, 2018, 6(3): 1010-1018.e2. DOI: 10.1016/j.jaip.2017.08.009.

36.Giavina-Bianchi P, Galvão VR, Picard M, et al. Basophil activation test is a relevant bi-omarker of the outcome of rapid desensitization in platinum compounds-allergy[J]. J Al-lergy Clin Immunol Pract, 2017, 5(3): 728-736. DOI: 10.1016/j.jaip.2016.11.006.

37.Kim SH, Kim SH, Chung SJ, et al. Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis[J]. Asia Pac Allergy, 2018, 8(1): e6. DOI: 10.5415/apallergy.2018.8.e6.

38.Campo P, Eguiluz-Gracia I, Bogas G, et al. Local allergic rhinitis: implications for manage-ment[J]. Clin Exp Allergy, 2019, 49(1): 6-16. DOI: 10.1111/cea.13192.

39.Eguiluz-Gracia I, Pérez-Sánchez N, Bogas G, et al. How to diagnose and treat local allergic rhinitis: a challenge for clinicians[J]. J Clin Med, 2019, 8(7): 1062. DOI: 10.3390/jcm8071062.

40.Nopp A, Cardell LO, Johansson SG, et al. CD-sens: a biological measure of immunological changes stimulated by ASIT[J]. Allergy, 2009, 64(5): 811-814. DOI: 10.1111/j.1398-9995.2008.01900.x.

41.Dahlén B, Nopp A, Johansson SG, et al. Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma[J]. Clin Exp Allergy, 2011, 41(8): 1091-1097. DOI: 10.1111/j.1365-2222.2011.03763.x.

42.Konradsen JR, Nordlund B, Nilsson OB, et al. High basophil allergen sensitivity (CD-sens) is associated with severe allergic asthma in children[J]. Pediatr Allergy Immunol, 2012, 23(4): 376-384. DOI: 10.1111/j.1399-3038.2011.01260.x.

43.Nopp A, Johansson SG, Ankerst J, et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation[J]. Allergy, 2006, 61(3): 298-302. DOI: 10.1111/j.1398-9995.2006.00987.x.

44.Stoevesandt J, Sturm GJ, Bonadonna P, et al. Risk factors and indicators of severe systemic insect sting reactions[J]. Allergy, 2020, 75(3): 535-545. DOI: 10.1111/all.13945.

45.Sturm GJ, Böhm E, Trummer M, et al. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study[J]. Allergy, 2004, 59(10): 1110-1117. DOI: 10.1111/j.1398-9995.2004.00400.x.

46.Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hy-menoptera venom allergy[J]. Allergy, 2018, 73(4): 744-764. DOI: 10.1111/all.13262.

47.Peternelj A, Silar M, Erzen R, et al. Basophil sensitivity in patients not responding to venom immunotherapy[J]. Int Arch Allergy Immunol, 2008, 146(3): 248-254. DOI: 10.1159/000116361.

48.Rodríguez Trabado A, Cámara Hijón C, Ramos Cantariño A, et al. Short-, intermediate-, and long-term changes in basophil reactivity induced by venom immunotherapy[J]. Allergy Asthma Immunol Res, 2016, 8(5): 412-420. DOI: 10.4168/aair.2016.8.5.412.

49.Korosec P, Turner PJ, Silar M, et al. Basophils, high-affinity IgE receptors, and CCL2 in hu-man anaphylaxis[J]. J Allergy Clin Immunol, 2017, 140(3): 750-758.e15. DOI: 10.1016/j.jaci.2016.12.989.

50.Yamaga S, Yanase Y, Ishii K, et al. Decreased intracellular histamine concentration and ba-sophil activation in anaphylaxis[J]. Allergol Int, 2020, 69(1): 78-83. DOI: 10.1016/j.alit.2019.05.009.

51.Hirayama F, Yasui K, Matsuyama N, et al. Possible utility of the basophil activation test for the analysis of mechanisms involved in allergic transfusion reactions[J]. Transfus Med Rev, 2018, 32(1): 43-51. DOI: 10.1016/j.tmrv.2017.09.002.

52.Matsuyama N, Hirayama F, Wakamoto S, et al. Application of the basophil activation test in the analysis of allergic transfusion reactions[J]. Transfus Med, 2009, 19(5): 274-277. DOI: 10.1111/j.1365-3148.2009.00939.x.

53.Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogen-esis, laboratory tests, prevention and treatment[J]. Br J Haematol, 2013, 160(4): 434-444. DOI: 10.1111/bjh.12150.

54.Yasui K, Matsuyama N, Kimura T, et al. Immunoglobulin (Ig)G antibodies against IgE iden-tified by basophil activation test as the putative causative agent of a serious allergic transfusion reaction: potential utility of the test as a new safety measure for allergic transfusion reactions[J]. Transfusion, 2018, 58(11): 2572-2580. DOI: 10.1111/trf. 14878.

55.Yasui K, Matsuyama N, Okamura-Shiki I, et al. Clinical utility of a passive immune basophil activation test for the analysis of allergic transfusion reactions[J]. Transfusion, 2017, 57(9): 2084-2095. DOI: 10.1111/trf.14208.

56.Yasui K, Takihara Y, Matsuyama N, et al. Sensitivity and specificity of passive im-mune-basophil activation test to detect allergic transfusion reactions[J]. Transfusion, 2019, 59(11): 3308-3313. DOI: 10.1111/trf.15542.

57.Novak N, Mete N, Bussmann C, et al. Early suppression of basophil activation during al-lergen-specific immunotherapy by histamine receptor 2[J]. J Allergy Clin Immunol, 2012, 130(5): 1153-1158.e2. DOI: 10.1016/j.jaci.2012.04.039.

58.Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response[J]. J Allergy Clin Immunol, 2015, 135(4): 913-921.e9. DOI: 10.1016/j.jaci. 2014.09.049.

59.Takahagi S, Tanaka A, Hide M. Sweat allergy[J]. Allergol Int, 2018, 67(4): 435-441. DOI: 10.1016/j.alit.2018. 07.002.

Hot Papers